[1] WANG LW,LI ZS,DE LS,et al. Prevalence and clinical features of chronic pancreatitis in China:A retrospective multicenter analysis over 10 years[J]. Pancreas,2009,38(3):248-254.
|
[2] CHEN Y,LI XQ. An excerpt of international consensus statements on early chronic pancreatitis(2018)[J]. J Clin Hepatol,2018,34(8):1639-1643.(in Chinese)陈洋,李晓青.《2018年早期慢性胰腺炎国际共识声明》摘译[J].临床肝胆病杂志,2018,34(8):1639-1643.
|
[3] HOU W,LIU B,XU H. Triptolide:Medicinal chemistry,chemical biology and clinical progress[J]. Eur J Med Chem,2019,176:378-392.
|
[4] CHEN SR,DAI Y,ZHAO J,et al. A mechanistic overview of Triptolide and celastrol,natural products from Tripterygium wilfordii Hook F[J]. Front Pharmacol,2018,9:104.
|
[5] NOEL P,VON HOFF DD,SALUJA AK,et al. Triptolide and its derivatives as cancer therapies[J]. Trends Pharmacol Sci,2019,40(5):327-341.
|
[6] WANG YJ,ZHANG M,MENG B,et al. Inhibitory effect of triptolide on growth of subcutaneous tumor of pancreatic cancer in nude mice and its mechanism[J]. J Jilin Univ(Med Edit),2019,45(2):234-238,470.(in Chinese)王云检,张珉,蒙博,等.雷公藤甲素对裸鼠胰腺癌皮下移植瘤生长的抑制作用及其机制[J].吉林大学学报(医学版),2019,45(2):234-238,470.
|
[7] KUSSKE AM,RONGIONE AJ,ASHLEY SW,et al. Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice[J]. Surgery,1996,120(2):284-288,discussion 289.
|
[8] MAJUMDER S,CHARI ST. Chronic pancreatitis[J]. The Lancet,2016,387(10031):1957-1966.
|
[9] WANG Y,LAN Y,GAO Y. Efficacy of endoscopic treatment for patients with chronic pancreatitis[J]. Clin J Med Offic,2019,47(11):1264-1265.(in Chinese)王叶,蓝宇,高岩.内镜治疗慢性胰腺炎患者疗效观察[J].临床军医杂志,2019,47(11):1264-1265.
|
[10] Chronic Pancreatitis Group of Pancreatic Disease Committee of Chinese Medical Doctor Association. Guideline for the diagnosis and treatment of chronic pancreatitis(2018,Guangzhou)[J]. J Clin Hepatol,2019,35(1):45-51.(in Chinese)中国医师协会胰腺病专业委员会慢性胰腺炎专委会.慢性胰腺炎诊治指南(2018,广州)[J].临床肝胆病杂志,2019,35(1):45-51.
|
[11] NADELLA S,CIOFOAIA V,CAO H,et al. Cholecystokinin receptor antagonist therapy decreases inflammation and fibrosis in chronic pancreatitis[J]. Dig Dis Sci,2019.[Epub ahead of print]
|
[12] ZHOU ZL,YANG YX,DING J,et al. Triptolide:Structural modifications,structure-activity relationships,bioactivities,clinical development and mechanisms[J]. Nat Prod Rep,2012,29(4):457-475.
|
[13] ZHANG SJ,ZHAI WL,ZHAO YF,et al. Triptolide treatment of severe acute pancreatitis in rats[J]. World Chin J Dig,2005,13(8):997-1001.(in Chinese)张水军,翟文龙,赵永福,等.雷公藤内脂醇对大鼠重症急性胰腺炎的治疗作用[J].世界华人消化杂志,2005,13(8):997-1001.
|
[14] WU X,ZHANG HF,QIANG H,et al. The effect of Triptolide by inhabit chemokine CXCL11 in severe acute pancreatitis[J]. J Nantong Univ(Med Sci),2013,33(1):31-34.(in Chinese)吴兴,张海峰,强晖,等.雷公藤内酯醇抑制CXCL11的表达对重症急性胰腺炎的影响[J].南通大学学报(医学版),2013,33(1):31-34.
|
[15] JAWOREK J,SZKLARCZYK J,KOT M,et al. Chemerin alleviates acute pancreatitis in the rat thorough modulation of NF-κB signal[J]. Pancreatology,2019,19(3):401-408.
|
[16] BHANOT UK,MÖLLER P. Mechanisms of parenchymal injury and signaling pathways in ectatic ducts of chronic pancreatitis:Implications for pancreatic carcinogenesis[J]. Lab Invest,2009,89(5):489-497.
|
[17] RAKONCZAY Z,HEGYI P,TAKACS T,et al. The role of NF-κB activation in the pathogenesis of acute pancreatitis[J].Gut,2008,57(2):259-267.
|
[18] TAN P,WANG A,CHEN H,et al. SPOP inhibits mice pancreatic stellate cell activation by promoting FADD degradation in cerulein-induced chronic pancreatitis[J]. Exp Cell Res,2019,384(1):111606.
|
[19] CUI J,CHEN X,SU JC. Advanced progress of main pharmacology activities of Triptolide[J]. China J Chin Mater Med,2017,42(14):2655-2658.(in Chinese)崔进,陈晓,苏佳灿.雷公藤甲素药理作用研究新进展[J].中国中药杂志,2017,42(14):2655-2658.
|